Valvular & structural heart diseaseSecondary analysis
Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation
- Secondary analysis of the DapaTAVI randomised trial
- prespecified analysis
Authors' conclusion
TAVI was associated with a substantial improvement in KCCQ scores. However, the addition of dapagliflozin following the procedure did not confer an additional benefit in health status compared with standard care.
Study context
- Population
- Patients with AS undergoing transcatheter aortic valve implantation (TAVI)with baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) scores
- Participants
- 964 patients
- Comparison
- Dapagliflozin vs no dapagliflozin after TAVI
- Primary endpoint
- Change in KCCQ score from baseline (ordinal logistic regression)
- Follow-up
- 3 and 12 months
Primary result
As reported in the abstract
Change in KCCQ score (OR for improvement)
Dapagliflozin vs ControlOdds ratio (95% CI)P value
3 months
0.96(0.72–1.26)
P = 0.74512 months
1.03(0.83–1.27)
P = 0.819Further findings
Clinically meaningful KCCQ improvement (>50 points) · 12 months
Death or worsening heart failure (HF) by baseline KCCQ score
- Clinical benefits of dapagliflozin appeared similar across the full range of baseline KCCQ scores
Original publication
Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation. J Am Coll Cardiol. Published 14 October 2025. doi:10.1016/j.jacc.2025.07.051
Summarised from the published abstract; every number is checked against it